Certain members of the indigenous biota of humans produce antimicrobial substances called bacteriocins, which inhibit other bacteria, including members of their own species. One of these substances, mutacin, is made by Streptococcus mutans, a member of the oral biota. Mutacin inhibits other mutans streptococci as well as many gram-positive exogenous pathogens. Here, we report for the first time the purification and partial biochemical characterization of a lanthionine-containing mutacin peptide from S. mutans T8. The biologically active peptide was-isolated from the broth cultures by ultrafiltration and differential precipitation. The final mutacin preparation was homogeneous as shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and N-terminal amino acid sequencing. A molecular mass of the peptide was estimated by electrospray ionization mass spectroscopy to be 3,244.64 + 1.15 Da. Its amino acid composition indicates the presence of lanthionine and likely ,B-methyllanthionine in a total of about 25 amino acids. Because a,,B-unsaturated amino acids, the precursors of lanthionine residues, are often found in lantibiotics, we carried out the addition reaction of the mutacin with N-(methyl)mercaptoacetamide. The subsequent electrospray ionization mass spectroscopy analysis indicated the presence of two reaction products with Mrs of 3,350.45 and 3,456.0. These are interpreted as the mutacin molecule with the addition of one and two molecules of reagent to the unsaturated amino acids, respectively. Sequencing of the peptide revealed an N-terminal amino acid sequence of Asn-Arg-Trp-Trp-Gln-Gly-Val-Val.
Several species of bacteria inhabiting the human oral cavity, including the mutans streptococci, produce antimicrobial substances referred to as bacteriocins or bacteriocin-like inhibitory substances (36) . These antimicrobial substances may be important for sustained colonization of indigenous bacteria in a densely populated milieu typified by plaque accumulation on the surfaces of teeth (17, 24) . In addition, these inhibitory substances may serve to exclude nonindigenous, potential pathogens from colonizing a susceptible host (37) . Different groups of mutans streptococci produce distinct bacteriocin-like inhibitory substances, or mutacins, including a subset from Streptococcus mutans designated a group II mutacin (6, 8, 30) . To date, most remain partially characterized (6, 11, 15, 18, 20, 25, 26, 30, 31) . Possible reasons for limited success in characterization of these substances include the observations that they are made in small quantities and only under special cultivation conditions and that mutacins may not be produced in, or are difficult to isolate from, liquid medium. In addition, the spectrum of activity and chemical and physical properties of mnutacins vary widely. This wide diversity in their inhibitory activity can be exploited, however, by a technique known as bacteriocin typing. Different strains of mutans streptococci can be distinguished by the inhibition pattern obtained with a panel of indicator strains (3, 10, 16, 24, 33) .
We initially became interested in mutacin production because of its association with a cryptic plasmid in S. mutans. We found that among strains of S. mutans harboring a 5.6-kb plasmid, at least two distinct but closely related mutacinproducing and immunity groups existed (6) . Subsequent studies showed, however, that mutacin production was not plasmid characterizing the chromosomal locus responsible for mutacin expression. The initial attempts to identify the gene(s) responsible for mutacin expression employed transpositional mutagenesis with transposon Tn916 as the mutagen. Five different chromosomal loci associated with mutacin expression have been identified (7) . Here we report the isolation and characterization of a group II mutacin from T8, a plasmid-free strain of S. mutans.
MATERUILS AND METHODS
Bacterial strains and media. S. mutans T8 was used in this study for the production and isolation of mutacin. Streptococcus sanguis NylO1, S. mutans 10449, or Streptococcus sobrinus OMZ176 was used as a sensitive indicator strain.
For the purpose of isolating mutacin from liquid culture, the producer was grown in a chemically defined medium (38) supplemented with yeast extract (Difco Laboratories, Detroit, Mich.) and Trypticase soy broth (Difco Laboratories). Preliminary activity assays showed that a 1:1 mixture (vol/vol) of chemically defined medium and Trypticase soy broth supplemented with 3% yeast extract resulted in the optimal recovery of mutacin from liquid culture.
All strains were stored frozen in Todd-Hewitt broth with 30% glycerol at -70°C until needed.
Mutacin assay. Mutacin production was detected on Trypticase soy-yeast agar by the deferred antagonism technique, as described previously (6, 30) . Mutacin present in liquid culture was quantified by spotting 25 RId of twofold dilutions of mutacin in phosphate-buffered saline (PBS) onto the surface of Trypticase soy-yeast agar overlaid with an indicator strain, as described above. Spots were allowed to dry for 1 h, and then the plates were incubated anaerobically for 24 h. The lowest titer yielding a zone of inhibition having clear edges was defined as one bacteriocin unit.
Mutacin purification. An overnight culture of strain T8 (200 ml) was used to inoculate 2 liters of production medium and then incubated anaerobically in a 2-liter flask for 48 h without agitation. Cultures were then subjected to a series of filtration and ultrafiltration steps as follows. Cells were first removed from the medium with a 0.45-p,m-pore-size membrane. The filtrate was then passed through a series of ultrafiltration membranes with molecular-mass cutoffs of 100, 10, and 1 kDa, respectively (Minitan; Millipore Corp., Bedford, Mass.). An equal volume of chloroform was added to the 1-kDa retentate (19) . The emulsion formed between the aqueous and chloroform layers was dried and washed with PBS. The protein was solubilized in 8 M urea and then precipitated by the addition of 20 volumes of water. Fractions of mutacin at different stages of the isolation and purification procedures were assayed for mutacin activity (spot test described above) and protein content (4). pH stability, thermostability, and sensitivity to trypsin.
Purified mutacin was mixed with different 0.1 M buffers with pH values of 4 to 11 (sodium acetate, pH 4 to 6; sodium phosphate, pH 7 to 8; glycine-NaOH, pH 8 to 11). After a 1or 24-h incubation at room temperature, residual mutacin activity was assayed by the spot test described above. Thermostability was assayed by analysis of residual biological activity present in a mutacin sample after incubation at pH 7 in a boiling water bath for up to 30 min. Sensitivity to trypsin (Sigma Chemical Co., St. Louis, Mo.) was determined according to the manufacturer's recommendation by incubating purified mutacin (4,096 bacteriocin units) in 50 ,u1 of 50 mM sodium phosphate buffer (pH 7.5) with trypsin (2 p.g) at room temperature. Samples were analyzed for residual mutacin activity at various intervals.
Size exclusion chromatography. Further characterization of mutacin was accomplished by high-performance liquid chromatography (HPLC) (27) . Samples for HPLC were dissolved in 0.5 M guanidine-50 mM Tris HCl (pH 7.0) and chromatographed in two tandemly arranged Bio-Sil SEC 125 columns (Bio-Rad Laboratories, Richmond, Calif.). The column effluent was monitored at 220 nm, and the elution time was compared with elution times for a standard set of peptide markers. SDS electrophoresis. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10-to-20% linear gradient Tricine gels (Jule Inc., New Haven, Conn.) (34) and detected by Coomassie blue staining. The samples were incubated with a loading buffer at 400C for 30 min or were boiled for 5 min and cooled to room temperature before the gel was loaded. Biological activity after a thorough wash of the gel was detected by the overlay, as described above, with S. sanguis NylOl as the indicator strain.
Amino acid analysis and sequencing. Purified mutacin was hydrolyzed in 6 N HCl, and the resultant amino acids were then analyzed by reverse-phase HPLC after precolumn derivatization with a hydrophobic fluorescent reagent (28) . Lanthionine (Sigma Chemical Co.) was included in the standard assays in addition to the common amino acids. The analysis of cysteine as cysteic acid was performed as described previously (29) .
Sequencing of the desalted mutacin was accomplished by automated Edman degradation with a gas-phase microsequencing system (Model PI 2090E; Porton Instrument Inc., Tarzana, Calif.). The system was equipped with an on-line phenylthiohydantoin-amino acid analyzer. Comparison of the mutacin N-terminal amino acid sequence with known se- (9) .
Electrospray ionization mass spectroscopy. The purified mutacin was analyzed by electrospray ionization mass spectroscopy on a PE Sciex API III Biomolecular mass analyzer. The detection of ao,-unsaturated amino acids was accomplished by electrospray ionization mass spectroscopy after derivatization with N-(methyl)mercaptoacetamide (23) . The reaction proceeded for up to 15 days at room temperature in 0.1 M ammonium acetate buffer (pH 5) with a 35-fold excess of the reagent (23) .
RESULTS
Purification of mutacin. The cultivation of mutacin-producing mutans streptococci in the liquid medium described here was pivotal in the isolation of mutacin. The roles of the individual components of this medium in promoting mutacin biosynthesis, however, are not known. Previous studies show that the addition of yeast extract to solid medium enhances the inhibitory activity of mutacin (6, 32) . Mutacin produced in the optimized medium was recovered in 10-kDa ultrafiltrate and 1-kDa retentate, suggesting an Mr between 10,000 and 1,000. Table 1 shows results of the purification procedure at different stages of isolation. The final preparation of mutacin was purified more than 84-fold and was over 90% pure (as determined by amino acid analysis). Purified mutacin subjected to HPLC with a size-exclusion column revealed a single peak with an Mr of about 2,500, as determined by comparison with the elution pattern of standard proteins. Tricine SDS gels showed a single band after Coomassie blue staining (Fig. 1A ). An overlay with an indicator strain correlated biological activity with the protein band (Fig. 1B) . The activities of the samples after incubation with a loading buffer at 40°C for 30 min or at 100°C for 5 min were compared. Both procedures yielded the active substance, as demonstrated by the appearance of inhibition zones in the overlay.
Biochemical characterization. Mutacin was thermostable (as indicated by analysis for residual activity after incubation in a boiling water bath for up to 30 min). It was stable after 24 h of incubation in different buffers (with a pH range of 4 to 10) at room temperature. Mutacin residual activity after incubation at pH 11 for 24 h dropped to about 50% activity. Trypsin inactivated the mutacin; after 10 min of incubation with trypsin, no activity in the sample was detected. Control samples without trypsin retained their full activity under identical conditions.
The probable amino acid composition of mutacin is given in Table 2 . The method employed for the analysis, however, did not allow the detection of tryptophan. Two unique peaks were evident in the analysis. The chromatographic positions indicated their potential derivation from lanthionine and 1-methyllanthionine. One of the peaks was subsequently identified as lanthionine by comparison with the elution position of authentic lanthionine derivatized with the standard reagent. The chromatographic position of the other peak was consistent with its identification as ,-methyllanthionine since that amino acid would be slightly more hydrophobic than lanthionine. To verify the findings, derivatization of the amino acids with phenylisothiocyanate and separation by an alternative gradient system were used. This experiment confirmed the results of the initial analysis.
Mutacin sequencing. Sequencing of the mutacin peptide revealed the following N-terminal amino acid sequence: Asn-Arg-Trp-Trp-Gln-Gly-Val-Val. No additional sequence was detected in the following cycles. Comparison of the obtained N-terminal sequence with known amino acid sequences in protein databases failed to reveal any meaningful homology.
Electrospray ionization mass spectroscopy. Analysis of the purified mutacin by electrospray ionization mass spectroscopy showed the peptide to have a molecular mass of 3,244.64 ± 1.15 Da (Fig. 2) . To investigate the possible presence of unsaturated amino acids in the mutacin molecule which might be the cause of the stopped sequencing after the valine residue, an addition reaction with N-(methyl)mercaptoacetamide was carried out. This thiol has an Mr of 105.2, and its addition to the mutacin molecule can be easily detected by the increase of the Mr of mutacin after the reaction. The mass spectroscopic analysis revealed two new components, besides the original mutacin, with Mrs of 3,350.48 and 3,456.0. This suggested the addition of one and two molecules of N-(methyl)mercaptoacetamide per molecule of mutacin, respectively. Even after prolonged incubation, when no original mutacin could be detected, both components (with Mrs of 3,350.48 and 3,456.0) were found. We conclude from these data that mutacin T8 likely contains two amino acid residues with unsaturated bonds.
DISCUSSION
This paper describes for the first time the isolation and partial characterization of a lanthionine-containing antibiotic from a human-derived strain of S. mutans. The success in isolating the mutacin could be attributed to the development of a liquid medium that fosters the production of the mutacin. Additional steps employing ultrafiltration and selective precipitation facilitated the purification process. A single, biologically active protein was isolated. Ion spray mass spectroscopic analysis showed its Mr to be 3,244.64 ± 1.15.
The mutacin was thermostable, stable in a wide range of pH values, and sensitive to trypsin. On the basis of its amino acid composition, mutacin possesses characteristics of a basic pro- tein. This agrees with its mobility in agar gels, as detected by a gel overlay with a sensitive indicator strain (results not shown).
The peptide was shown to contain lanthionine and also likely contains a related amino acid, ,B-methyllanthionine. These data, together with other findings, suggest that the T8 mutacin is a member of the lanthionine-containing polypeptide family. Other lanthionine-containing peptides produced by grampositive species include nisin from Lactococcus lactis, epidermin from Staphylococcus epidermidis, and subtilin from Bacillus subtilis (1, 12, 14) .
The N-terminal amino acid sequence of the mutacin as determined by Edman degradation was unique compared with known sequences in the protein databases. The absence of methionine at the N terminus suggests that mutacin may be processed from a precursor form, as reported for other lantibiotics (5, 22, 39) . Additional cycles did not reveal any phenylthiohydantoin-amino acid derivatives. Both lanthionine and 13-methyllanthionine are suitable for cleavage from the protein by the Edman procedure. Edman cleavage of a residue contributing to lanthionine or ,-methyllanthionine would result in a blank cycle, but sequencing should continue uninterrupted. Because the sequencing did not proceed, we hypothesize that posttranslational modifications of mutacin leading to the formation of aot,-unsaturated amino acids might be the basis for the failure to remove further amino acids. These unsaturated amino acids, which are precursors of the lanthionine residues, have been responsible for cessation of sequencing in several lantibiotics (12, 13, 23) . To further investigate the possible presence of unsaturated amino acids in the mutacin molecule, an addition reaction with N-(methyl)mercaptoacetamide was carried out. Ion spray mass spectroscopic analysis indicated the presence of components with Mrs of 3,350.48 and 3,456.0. These two components are interpreted as mutacin with the addition of one and two molecules of N-(methyl)mercaptoacetamide, respectively. However, it is not clear why the reaction did not yield a homogeneous derivative with two molecules of N-(methyl)mercaptoacetamide, even after 15 days of incubation. This heterogeneity is likely to originate from the presence of one unsaturated residue in some molecules and two such residues in other molecules.
Elucidation of the complete primary structure of mutacin might be addressed by the sequencing of shorter peptides after cleavage of the protein with different proteases (2) . Alternatively, the identification of the structural gene should yield the amino acid sequence as well as provide information about regulation and processing of mutacin, as was shown before with nisin and epidermin (21, 35) . Further research will employ techniques of both spectral analysis and molecular genetics. This will provide new information on the structural and functional properties of this novel and promising lantibiotic.
